

Structural and Biophysical Characterization of Thanatin Peptidomimetics Binding to LptA of Critical Gram-Negative Pathogens

Dissertation

zur

Erlangung der naturwissenschaftlichen Doktorwürde

(Dr. sc. nat.)

vorgelegt der

Mathematisch-naturwissenschaftlichen Fakultät

der

Universität Zürich

von

Kathryn K. Oi

aus

Vereinigte Staaten von Amerika

Promotionskommission

Prof. Dr. Oliver Zerbe (Vorsitz)

Prof. Dr. Leo Eberl

Prof. Dr. Jörn Piel

Dr. Daniel Obrecht

Zürich, 2023

Table of Contents

| | |
|---|------------|
| Abbreviations | iv |
| Summary | vii |
| Chapter 1: Introduction | 1 |
| 1. <i>Background</i> | 2 |
| 1.1 The Global Burden of Antimicrobial Resistance (AMR) | 2 |
| 1.2 The Drugs and Bugs | 3 |
| 1.3 Outline of Subsequent Sections | 4 |
| 2. <i>Bacterial Barriers and Resistances</i> | 7 |
| 2.1 Intrinsic Resistances | 7 |
| 2.1.1 The Bacterial Envelope | 8 |
| 2.1.2 Porins | 10 |
| 2.1.3 Self-Promoted Pathway | 13 |
| 2.1.4 Efflux | 14 |
| 2.1.5 Conclusion | 15 |
| 2.2 Adapted Resistance Mechanisms | 15 |
| 2.2.1 Antibiotic Inactivation | 15 |
| 2.2.2 Target Modification | 18 |
| 2.2.3 Conclusion | 21 |
| 2.3 Acquired Resistance Mechanisms | 21 |
| 2.3.1 Horizontal Gene Transfer | 22 |
| 2.3.2 Conclusion | 22 |
| 2.4 Summary | 22 |
| 3. <i>Natural Product Antimicrobials</i> | 23 |
| 3.1 Cationic Antimicrobial Peptides | 23 |
| 3.1.1 Peptidomimetics | 24 |
| 4. <i>LPS Transport</i> | 27 |
| 5. <i>Aims of the Thesis and Structure of the Following Sections</i> | 29 |
| 6. <i>References</i> | 31 |
| Chapter 2: Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae | 35 |
| <i>Abstract</i> | 36 |

| | |
|---|----|
| 1. Introduction | 37 |
| 2. Results | 38 |
| 2.1 Drug Discovery | 38 |
| 2.2 Structural Determinants of Thanatin Resistance | 41 |
| 2.3 Biological Profiling | 43 |
| 2.4 Pharmacology <i>in vitro</i> and <i>in vivo</i> | 44 |
| 2.5 Mode-of-Action Studies: Interactions of Lpt Proteins in the Periplasmic Bridge..... | 45 |
| 2.6 Disassembly of the Periplasmic Bridge by Compound 7 | 46 |
| 3. Discussion..... | 47 |
| 4. Materials and Methods | 49 |
| 5. References..... | 60 |
| 6. Supplementary Materials..... | 62 |
| 7. Unpublished Supplementary Materials | 98 |

Chapter 3: Early Molecular Insights into Thanatin Analogues Binding to *A. baumannii* LptA

102

| | |
|---|-----|
| <i>Abstract</i> | 103 |
| 1. Introduction | 104 |
| 2. Results..... | 106 |
| 2.1 Protein Characterization and Quality Control | 106 |
| 2.2 Structural Studies by Nuclear Magnetic Resonance (NMR)..... | 108 |
| 2.3 Fluorescence Polarization Binding Studies | 110 |
| 2.4 Examining the Affinities of Thanatin Derivatives..... | 112 |
| 2.5 Conserved Binding Mode of 7 to LptAm across Phyla..... | 112 |
| 3. Discussion and Outlook..... | 115 |
| 4. Materials and Methods..... | 118 |
| 5. References..... | 121 |
| 6. Supplementary Materials..... | 123 |

Chapter 4: General Discussion

136

| | |
|--|-----|
| 1. Key Findings..... | 137 |
| 1.1 Thanatin Peptidomimetics and Enterobacteriaceae LptA..... | 137 |
| 1.2 Thanatin Peptidomimetics and <i>A. baumannii</i> LptA..... | 138 |

| | |
|---|------------|
| 2. <i>Limitations</i> | 140 |
| 3. <i>Future Research</i> | 141 |
| 3.1 Uptake Studies | 141 |
| 3.2 Next Steps for <i>A. baumannii</i> and Beyond | 141 |
| 4. <i>Shifting the Paradigm for AMPs as Antibiotics</i> | 142 |
| 4.1 Advantages | 142 |
| 4.2 Disadvantages | 143 |
| 5. <i>Concluding Remarks</i> | 144 |
| 6. <i>References</i> | 145 |
| Acknowledgements | 146 |
| Curriculum Vitae | 149 |